DNA methylation biomarker in blood predicts frailty

in an HIV-positive veteran population

Chang Shu[1,2], Amy C. Justice[1,2], Xinyu Zhang[1,2], Vincent C. Marconi[3], Dana B. Hancock[4], Eric O. Johnson[4,5], Ke Xu[1,2]

1. Department of Psychiatry, Yale School of Medicine, New Haven, CT, 06516

2. Connecticut Veteran Healthcare System, West Haven, CT, 06515

3. Division of Infectious Disease, Emory University School of Medicine, Atlanta GA

4. Center for Omics Discovery and Epidemiology, Behavioral Health Research Division, RTI International, Research Triangle Park, NC, USA

5. Fellow Program, RTI International, Research Triangle Park, NC, USA.

All corresponding address to

Ke Xu, M.D., Ph.D.

Associate Professor of Psychiatry

Yale School of Medicine

Email: ke.xu@yale.edu

Tel: 203-932-5711x7430

Abstract

Background: With the improved life expectancy in people living with HIV, predicting individual frailty is important for clinical care. DNA methylation (DNAm) has emerged as a robust biomarker in precision medicine and has been previously linked to aging and mortality in non-HIV populations. Here, we aim to establish a panel of DNAm features selected from blood methylome to predict frailty in HIV-positive men from a veteran population, Veterans Aging Cohort Study (VACS).

Methods: We used a well-established score, VACS Index, as a measure of frailty. Samples (n_{total}=1,150) were divided into a training set (n=612) and a validation set (n=538). We first selected a panel of frailty-associated CpGs by conducting an epigenome-wide association analysis on the VACS index in the training set. We then applied four machine learning methods to build models to predict high and low frailty individuals in the training set. The prediction models were tested in the validation set. A methylation score constructed from the selected CpGs was tested an associated with mortality by performing survival analysis. To assess the biological relevance of the selected CpG sites, we performed a gene ontology enrichment analysis.

Results: A panel of 119 CpGs were identified from the training set (False Discovery Rate <0.2) that showed excellent performance on predicting high frailty individuals with Area Under Curve (AUC) of 0.835 (95%CI: 0.792, 0.879) and balanced accuracy of 0.693. The same panel showed good performance on predicting low frailty individuals with AUC of 0.735 (95%CI: 0.688-0.782) and a balanced accuracy of 0.528. The methylation score from the 119 CpGs was significantly associated with 5-year and 10-year mortality with hazard ratio of 1.40 (95% CI:1.033, 1.897 p=0.03) and 1.48 (95%CI:

1.10, 2.02; p=0.01) respectively. These 119 CpGs were located within or near 73 genes

that were significantly enriched in 9 biological pathways relevant to immune and

inflammation response.

Conclusions: We identified a panel of predictive DNAm features associated with frailty

and mortality among HIV-positive population. These DNAm features may serve as

biomarkers to discriminate high and low frailty people who live with HIV.

Keywords: DNA methylation, HIV-positive, frailty, mortality, DNA methylation score,

machine learning prediction

Background

Combination antiretroviral therapy has significantly improved life expectancy among HIV-positive individuals. The prolonged life expectancy increases frailty risk in the HIV population. The prevalence of frailty in people living with HIV is significantly higher and onset of frailty occurs at an earlier age compared to the general population (1). High frailty is characterized by marked vulnerability and is associated with increased mortality. Thus, prediction of frailty is important to identify vulnerable group and deliver clinical care to highly vulnerable HIV-positive patients. At present, frailty is usually defined by clinical symptoms (e.g., Fried's frailty phenotype, Rockwood and Mitnitski's Frailty Index) or a combination of lab tests that indicate organ damage such as the Veterans Aging Cohort Study index (VACS index) (2). No biomarkers available to capture the early stage of the frailty to predict individual vulnerability in HIV-positive patients.

A large body of evidence has demonstrated that epigenetic modification adapts internal and external environmental changes and that is associated with early stage of pathophysiological processes (3-6). DNAm, one type of the most widely studied epigenetic marks, is strongly related with aging (7-9), substance use (e.g. cigarette smoking and alcohol consumption) (10-16), and a variety of diseases (3-6, 17, 18). Because DNAm is relatively stable and easy to detect from body fluids biospecimen through non-invasive procedure, DNAm marks have emerged as robust biomarkers for cancer diagnosis (19), disease subtype classification (20, 21) and treatment response monitoring (22, 23).

DNAm may play an important role in frailty among HIV-positive individuals. Frailty

is associated with elevated inflammation markers such as IL-6 and hsCRP in HIV-

positive individuals (24). Genes involved in immune and inflammation processes are

also subject to epigenetic modification in immune cells. We previously reported

association of two CpG sites in the promoter region of *NLRC5* with HIV infection (25),

and *NLRC5* gene is a major transcriptional activator of MHC class I gene. DNAm was

also linked to HIV comorbid medical diseases such as HIV-positive diabetes and kidney

function (26, 27). Furthermore, aging, a critical contributor to frailty, is significantly

associated with thousands of CpGs in the epigenome, and the epigenetic clock and

DNAm age are becoming widely recognized (7-9). DNAm age is significantly correlated

with physical frailty in HIV-negative individuals (28) and HIV-positive individuals (29). In

HIV-positive individuals, the average DNAm age is accelerated 5 to 10 years faster than

HIV-negative individuals (30-33) and 10 years faster in the HIV-positive frailty

individuals in comparing to HIV-positive non-frailty individuals (29). These age-related

DNAm signatures are predictive of mortality (34-38). Additional CpGs in blood have

been identified to predict all-cause mortality (34, 39). Therefore, we hypothesize that

DNAm is associated with frailty and that DNAm signatures in blood can serve as

biomarkers to predict frailty and mortality among HIV-positive individuals.

In this study, our goal is to identify DNAm marks that can serve as biomarkers

on frailty and to link frailty-associated DNAm to mortality among HIV-positive

individuals. We also evaluated biological relevance of the identified CpG sites. We used

a well-established frailty score, VACS index, as a measure of frailty in the HIV-positive

population. The VACS index is a composite score constructed by a sum of pre-assigned

points on age, CD4 count, HIV-1 RNA, hemoglobin, platelets, aspartate and alanine

transaminase (AST and ALT), creatine, estimated glomerular filtration rate (eGFR), and

viral hepatitis C infection (40). Findings from this study provide a set of DNAm

biomarkers to predict frailty for future clinic use and new insights into the epigenetic

mechanism of frailty and mortality in HIV pathology.

Methods

As an overview, our analytical procedure is shown in the flowchart in **Figure 1**.

Our sample was divided into the training set (n=612) and the validation set (n=538)

which DNA methylation were processed at different time and using two different

platforms. We first selected a panel of CpG sites relevant to frailty based on EWAS

results in the training set. Then, we applied four commonly used machine learning

classification methods to develop prediction models: random forest, Extreme Gradient

Boosting Tree (XGBoost), Lasso and Elastic-Net Regularized Generalized Linear

Models (GLMNET), and Support Vector Machines (SVM). The selected CpG sites were

used as predictors to differentiate high and low frailty in the training set and each model

was evaluated in the validation set. Additionally, the DNAm score was constructed

based on the selected CpG sites and we conducted survival analysis to assess whether

the DNAm score was associated with mortality in the HIV-positive samples. Lastly, we

conducted a gene ontology enrichment analysis to reveal the underlying biological

pathways of the selected CpG sites.

Study population

All samples in the training and validating sets were from the VACS cohort. The

VACS is a prospective cohort study of veterans focusing on clinical outcomes in HIV

infection (41). DNA samples were extracted from peripheral blood of 1,150 HIV-positive

men from the VACS. Demographic and clinical information on age, race, smoking

status, CD4 count, viral load, HIV medication adherence, VACS index, and mortality by

training set and validation set are presented in **Table 1**. The training set included slightly

older individuals, more African Americans, and greater VACS index than the validation

set. There was no significant difference in HIV medication adherence, CD4 count, or

$\log_{10}$ HIV-1 viral load between the training set and the validation set.

Table 1: Study sample characteristics

	Training set (N=612)	Validation set (N=538)	p value*
Age (year, mean +/-sd)	49.4 (7.6)	48.1 (7.8)	0.005
Male (%)	612 (100)	538 (100)	
Race (%)			
Caucasian	58 (9.5)	48 (8.9)	0.001
African Americans	526 (85.9)	435 (80.9)	
Other	28 (4.6)	55 (10.2)	
Smokers (%)	360 (59.4)	309 (58.4)	0.78
HIV positive (%)	614 (100)	538 (100.0)	
HIV treatment adherence (%)	469 (78.4)	407 (76.6)	0.519
CD4 count	428.97 (286.33)	447.46 (279.27)	0.287
log 10 HIV-1 viral load	2.61 (1.19)	2.67 (1.23)	0.423
VACS index (mean +/-)	35.64 (21.99)	30.78 (20.23)	<0.001
Mortality (%)	162 (26.5)	129 (24.0)	0.367

  *t test is used for continous variables, chi-square test is used for categorical variables

Genome-wide DNAm profiling and quality control

The DNA samples in the training set were profiled by Infinium Human Methylation 450K

BeadChip (HM450K) and the DNA samples in the validation set were profiled by the

Infinium Human Methylation EPIC BeadChip. DNAm for the training and validation sets

were evaluated using the same quality control (QC) protocol (42) in the R package minfi

(43). In detail, CpG sites on sex chromosomes and within 10 base pairs of a single

nucleotide polymorphism were removed. The detection p-value threshold was set at 10^{-12}

for both the training and validation sets. After QC, 408,583 shared CpG sites between

HM450K and EPIC arrays were used for analysis to ensure the same coverage

between two sets. Proportions of 6 cell types (CD4+ T cells, CD8+ T cells, Natural Killer

T cells, B cells, monocytes and granulocytes) were estimated using the established

method (Houseman et al., 2012) for all samples in the training and validation sets.

Selection of CpG sites from EWAS on frailty in the training set

We performed an EWAS on VACS index in the training set using a two-step

linear model approach as previously described (42). The analytical model was adjusted

for systematic errors and clinical confounding factors. Here, log transformation was

applied to VACS index to ensure normality distribution assumption for the linear model.

First, the following linear model was used to extract principal components (PCs)

for potential confounding variables. Here, top 30 control PCs were derived from internal

control probes in *minfi*:

Methylation β ~ age + race + smoking + self-reported HIV medication adherence

+ log viral load + WBC + CD4T + CD8T + Gran + NK + B cell + Mono + 30 Control PCs

Second, the top 20 residual PCs were extracted in the model above to fully

adjust for unmeasured confounding. The final EWAS model on VACS index was:

log(VACS) ~ Methylation β + age + race + smoking + self-reported HIV

medication adherence + log viral load + WBC + CD4T + CD8T + Gran + NK + B cell +

Mono + 30 Control PCs + 20 Residual PCs

To ensure a sufficient number of CpGs as predictors for the prediction model

development, we selected CpG sites with false discovery rate (FDR) <0.2 in the EWAS

as predictors.

Additionally, to explore the underlying epigenetic mechanism of frailty, we also

detected differentially methylated regions (DMRs) using *bumpHunter* (44) in the training

set. DMRs with family-wise error rate (FWER)<0.2, which is equivalent to FDR<0.03,

were considered significant.

Developing machine learning prediction models for frailty

Based on the distribution of the VACS index in the entire sample (**Figure S1**) and

clinical significance (45), high HIV frailty was defined as VACS index > 50, and low HIV

frailty was defined as VACS index < 16. Models were developed to predict high frailty

(VACS index >50 versus ⩽50) and low frailty (VACS index <16 versus ≥16). CpGs

relevant to frailty were selected from EWAS as described above. The following steps

were taken to develop separate prediction models on high and low frailty:

1) Model development in the training set: Four machine learning models, random

forest, Extreme Gradient Boosting Tree (XGBoost), support vector machines(SVM),

Lasso and Elastic-Net Regularized Generalized Linear Models (GLMNET), were

separately applied to predict VACS index by using the R package *caret* (46). These four

models are commonly used in the supervised learning on classification (47-50). Each

model was developed separately and 10-fold cross-validation was used in model

training process to minimize data overfitting.

2) Model evaluation in the validation set: All four models built in the training set

were evaluated in the validation set. Area Under Curve (AUC) and balanced accuracy

were used to assess the prediction performance. We used balanced accuracy for model

evaluation because in the presence of imbalance samples in each class since there are

228 subjects with VACS index greater than or equal to 50 and 916 subjects with VACS

index less than 916. Balanced accuracy is defined as the average accuracy obtained on

each class as shown in the following formula (51). Balanced accuracy was used in this

study to avoid biased accuracy due to imbalanced samples (51).

$Balanced\ accuracy$

188
$$= \frac{1}{2}\left(\frac{True\ positive}{True\ positive + False\ negative} + \frac{True\ negative}{True\ negative + False\ positive}\right)$$

Association of a DNAm score for VACS index with mortality

We constructed a DNAm score by the selected frailty-associated CpG sites. A

survival analysis was conducted to assess whether the DNAm score was associated

with 5-year and 10-year mortality respectively.

DNAm score was constructed based on a previously reported method (12). We

computed the DNAm score by normalizing the score with mean β value (μ_c) and

standard deviation, σ_c, from subjects with VACS index <50 (control group). For selected

n methylation sites, W_c is 1 for a hypermethylated methylation site c, and -1 for a

hypomethylated site c, β_{ci} is the β value for subject i and methylation site c. The

methylation score for subject i was constructed by the following formula:

200
$$Methylation\ Score_i = \frac{1}{n}\sum_{c=1}^{n} W_c \frac{\beta_{ci} - \mu_c}{\sigma_c}$$

The mean methylation score was 0, and samples were divided into high

methylation score (>0) and low methylation score (⩽0) groups.

We preformed Kaplan-Meier survival curves during 10-year follow-up to visualize

the survival differences between high and low methylation score groups. Survival

analysis was conducted by cox proportional hazards model on 5-year and 10-year

mortality comparing high and low methylation groups. We used age as time scale t, and

our model was adjusted for race, smoking, self-reported HIV medication adherence, log

10 of HIV viral load and CD4 count.

$h(t) = h_0(t)\exp\,(\beta_1\ methylation\ score\ +\ \beta_2\ race\ +\ \beta_3\ smoking$

$\qquad\qquad +\ \beta_4\ HIV\ medication\ adherence\ +\ \beta_5\ \log_{10}(viral\ load) +\ \beta_6\ CD4\ count)$

Biological interpretation of the predictive panel of CpG sites on frailty

We performed gene ontology (GO) enrichment analysis using Database for

Annotation, Visualization and Integrated Discovery (DAVID) (52). To avoid redundancy

in pathway names, we only used level 4 GO terms defined in DAVID in the enrichment

analysis. Genes with at least one frailty-associated CpG site was used for GO analysis.

We considered biological pathways with FDR <0.05 as statically significant pathways.

Results

Selection a panel of 119 frailty-associated CpG sites by EWAS in the training set

In the training set, we conducted an EWAS on VACS index (**Figure 2**; λ=1.038) and

selected 119 CpGs with FDR<0.2 to ensure sufficient number of predictors (**Table 2)**.

Eighty out of 119 CpGs were negatively associated with VACS index, while 39 out of

119 CpGs were positively associated with VACS index. The majority of CpGs were

located within or near known genes, except for 19 CpGs that were intergenic. Only 40

CpGs were located in gene bodies, while 79 CpGs were located in promoter regions,

first exons, or 3' UTR. Thirty-two CpGs were located in CpG islands.

Notably, 22 out of 119 CpGs reached epigenome-wide significance (FDR<0.05),

including 16 CpG sites negatively associated with the VACS index and 6 CpG sites with

positive associations. These 22 CpGs were located on 17 genes, including 13 of 22

CpGs located in promoter regions, 6 CpGs in gene body, and 3 CpGs in 3'UTR. Among

these genes, some harbored more than one significant CpG. For example, three CpGs

were annotated within or near *PSMB8* (cg01309328, p=4.44×10^{-9}; cg08099136,

p=4.63×10^{-9}; cg00533183, p=3.18×10^{-7}), two CpGs were located near *PARP9*

(cg08122652, p=2.18×10^{-7}; cg22930808, p=6.78×10^{-7}), two CpG sites were located

near *IFITM1* (cg03038262, p=5.83×10^{-7}; cg23570810, p=1.58×10^{-6}), and the rest of the

significant CpG sites were annotated to 13 genes including *MX1*, *TAP1*, *ZNF32*,

NLRC5, *IFI44L*.

We found 9 significant DMRs in the training set (**Table S1**). Methylation β values

between high and low frailty ranged from -0.15 to 0.05 in these regions. As examples, 3

region plots showing DMRs in the *MX1, PARP9, and IFI44L* genes are shown in **Figure**

3.

Machine learning prediction on frailty by the selected 119 CpGs

Table 3: Performance of machine learning model predicting frailty in an HIV-infected population

| Method | High frailty (VACS index >50 vs. ≤50) | | | | Low frailty (VACS index >16 vs. ≤16) | | | |
| | Training | | Validation | | Training | | Validation | |
	AUC	Balanced Accuracy	AUC	Balanced Accuracy	AUC	Balanced Accuracy	AUC	Balanced Accuracy
Random Forest	0.775	0.622	0.835 (0.792,0.879)	0.693	0.774	0.509	0.735 (0.688,0.782)	0.528
XGBoost	0.760	0.624	0.830 (0.786,0.874)	0.684	0.820	0.637	0.716 (0.669,0.762)	0.500
GLMNET	0.783	0.642	0.757 (0.701,0.813)	0.668	0.795	0.589	0.715 (0.667,0.763)	0.503
SVM	0.759	0.618	0.744 (0.685,0.802)	0.500	0.756	0.594	0.501 (0.442,0.560)	0.492

AUC: Area Under Curve
VACS: Veteran Aging Cohort Study
XGBoost: Extreme Gradient Boosting Tree
GLMNET: Lasso and Elastic-Net Regularized Generalized Linear Models
SVM: Support Vector Machines
245

246   In the training set, we developed our prediction models based on the selected

119 CpGs in the training set using four commonly used machine learning classification

models: XGBoost, random forest, SVM and GLMNET (47-50). Performances of four

prediction models are presented in **Table 3**. We found that AUCs ranged from 0.756 to

0.820 and balanced accuracies ranged from 0.509 to 0.642, suggesting that the 119

CpGs had good to excellent predictive performance on frailty. The performances of four

models were mostly comparable. For predicting high frailty, GLMNET outperformed the

three other models (AUC=0.783, balanced accuracy=0.642) while SVM performed

slightly worse (AUC=0.759, balanced accuracy = 0.618). For the prediction of low frailty,

XGBoost performed the best among the four models (AUC=0.820, balanced

accuracy=0.637) while SVM performed worst (AUC=0.756, balanced accuracy =0.594).

In the validation set, for the prediction of high frailty, random forest and XGBoost

showed the best performance. AUC of random forest model was 0.835 (95%CI: 0.792,

0.879) and XGBoost was 0.830 (95%CI: 0.786, 0.874) for predicting high frailty.

Balanced accuracy was 0.69 and 0.68, respectively, for random forest and XGBoost

(**Figure 4**). For the prediction of low frailty, XGBoost and random forest models also

outperformed GLMNET and SVM. AUC was 0.735 (95%CI: 0.688, 0.782) for the

random forest and 0.716 (95%CI: 0.669, 0762) for the XGBoost. The balanced accuracy

was 0.528 and 0.500 for the random forest and XGBoost, respectively.

These results suggest that the selected panel of 119 CpG sites were able to

predict frailty, and the prediction models performed better at predicting high frailty than

predicting low frailty. Among four machine learning methods, SVM showed poor

performance of predicting frailty in our samples.

DNAm score by 119 CpGs was significant associated with mortality

We constructed DNAm score based on the selected 119 CpGs, and we further

assessed whether VACS index-related DNAm score were associated with mortality. In

Figure 5, the Kaplan Meier curves during 10-year follow-up showed that the individuals

with high DNAm score were at higher risk of mortality than those with low DNAm

scores. After adjusting for confounding factors, our cox proportional hazards regression

model showed that the hazard ratio of 5-year and 10-year mortality comparing high and

low DNAm score groups were 1.40 (95%CI: 1.03-1.90, p=0.03) and 1.48 (95%CI: 1.10-

2.02, p=0.01) respectively. In conclusion, we found that the DNAm score constructed

from the 119 selected CpGs was significantly associated with mortality.

Biological interpretations of 119 CpGs by gene ontology enrichment analysis

The selected panel of 119 CpGs were located within or near 73 genes. Gene

ontology enrichment analysis using these 73 genes resulted in 9 significant pathways

with FDR<0.05 (**Figure 6, Table 4**). These pathways included response to type I

interferon response (FDR=1.05×10^{-7}), innate immune response (FDR=3.45×10^{-5}),

cytokine response (FDR=3.69×10^{-3}) and defense response to virus (**Figure 6**). Our

findings suggested that the selected 119 CpG sites are biologically relevant to HIV

pathogenesis and progression.

Table 4: Gene ontology term enrichment analysis of the selected CpG sites that predict frailty in an HIV infected population

Term	N	%	Genes	Fold Enrichment	P value	FDR
GO:0034340~response to type I interferon	10	11.8	*OAS2, IFITM1, IFIT3, MX1, NLRC5, HLA-F, XAF1, HLA-E, IRF7, PSMB8*	28.1	6.62E-11	1.05E-07
GO:0045087~innate immune response	19	22.4	*TRIM22, MAP4K2, IFITM1, TRIM25, MX1, GFI1, IFIT5, XAF1, LY86, PSMB8, TRIM14, PARP9, PLSCR1, OAS2, IFIT3, NLRC5, HLA-F, HLA-E, IRF7*	5.0	2.17E-08	3.45E-05
GO:0051607~defense response to virus	11	12.9	*TRIM22, PLSCR1, OAS2, IFITM1, TRIM25, IFIT3, MX1, IFI44L, NLRC5, IFIT5, IRF7*	10.5	7.55E-08	1.20E-04
GO:0051707~response to other organism	18	21.2	*TRIM22, PDE4B, EPO, IFITM1, NOTCH1, TRIM25, MX1, GFI1, IFIT5, IFI44L, LY86, PLSCR1, OAS2, IFIT3,*	4.8	1.17E-07	1.85E-04

			CCDC88B, NLRC5, HLA-E, IRF7			
GO:0016032~viral process	19	22.4	TRIM22, IFITM1, TFRC, NOTCH1, TRIM25, MX1, PPIB, GFI1, IFIT5, IFI44L, TAP1, PSMB8, TRIM14, PLSCR1, OAS2, SLC1A5, IFIT3, NLRC5, IRF7	4.3	1.93E-07	3.07E-04
GO:0009615~response to virus	11	12.9	TRIM22, PLSCR1, OAS2, IFITM1, TRIM25, IFIT3, MX1, IFI44L, NLRC5, IFIT5, IRF7	7.7	1.27E-06	2.02E-03
GO:0098542~defense response to other organism	13	15.3	TRIM22, PLSCR1, OAS2, IFITM1, TRIM25, IFIT3, MX1, CCDC88B, IFIT5, NLRC5, IFI44L, HLA-E, IRF7	5.8	1.94E-06	3.09E-03
GO:0034097~response to cytokine	16	18.8	TRIM22, EPO, IFITM1, TRIM25, MX1, GFI1, XAF1, PSMB8, PARP9, PLSCR1, OAS2, IFIT3, NLRC5, HLA-F, HLA-E, IRF7	4.4	2.32E-06	3.69E-03
GO:0034341~response to interferon-gamma	8	9.4	TRIM22, OAS2, IFITM1, TRIM25, NLRC5, HLA-F, HLA-E, IRF7	10.9	7.95E-06	1.26E-02

Discussion

In this study, we present evidences that DNAm marks in blood are predictive of

frailty and are associated mortality in an HIV-positive population. We identified a panel

of 119 CpG sites that were highly predictive for high frailty and moderately predictive for

low frailty. We also found that the DNAm score constructed by these 119 CpGs was

strongly associated with mortality in the HIV-positive population. More importantly, these

clinically informative 119 DNAm features lied in genes involved in HIV pathogenesis and

progression. Thus, we discovered a panel of 119 DNAm biomarkers that add knowledge

to the epigenetic mechanisms underlying frailty and mortality among people living with

HIV.

We demonstrated the utility of using DNAm marks to predict frailty in HIV-positive

individuals. We took the several steps to avoid overfitting in developing the prediction

models: 1) model development and evaluation were conducted separately in training set

and validation set. DNAm in two sets were profiled in different time with different

platforms; 2) 10-fold cross validation were performed during training in each model. The

performances of four machine learning methods were in general consistent except that

the SVM did not perform well for low frailty. Our results suggested that this panel of

CpG sites was relatively stable and robust although performances of predictive models

differed using different methods. Of note, SVM showed the worst performance in

predicting high and low frailty that highlights the importance of choosing appropriate

machine learning method for model development. Compared to our previously reported

a panel of 698 smoking-associated CpGs that are moderately predictive of frailty (15),

the panel of 119 CpG sites in the present study includes fewer CpGs (119 CpGs) and

shows greater prediction performance on frailty (AUC=0.73 for smoking-associated

CpGs and AUC 0.83 for the VACS index-associated CpGs), suggesting that the panel

of 119 CpG sites has greater clinical utility for frailty among people living with HIV. The

improvement of prediction performance on frailty in the present study may be due to

different strategies of CpG selections. In this study, the 119 CpGs are selected from the

entire blood methylome and may be more informative than the smoking-associated

CpGs in our previous report.

We also found that the VACS index-related DNAm score derived from the 119

CpGs is strongly associated with mortality. This result provides further knowledge of

epigenetic profile into previous report that VACS index is predictive of mortality in

people who live with HIV (53). The result is also consistent with previous literature

showing that DNAm marks in blood predict mortality in the general population (39).

Interestingly, we found no overlapped CpG between our predictive panel and the

previously identified CpGs for all-cause mortality that included CpGs associated with a

variety of diseases such as diabetes and cancer(39). The discrepancy suggest that

methylation-based prediction of mortality may be relevant to causal disease. A recent

study reports a significant overlap of mortality-associated CpGs and aging-associated

CpGs (Lund et al, 2019). We found no overlapped CpG site between our mortality-

related 119 CpG panel and aging-related 353 CpGs in epigenetic clock (7), suggesting

that epigenetic mechanisms in HIV-related mortality differ from aging-related mortality.

Most importantly, this panel of 119 CpG sites are biologically meaningful and

may shed light on our understanding of the biological mechanisms of frailty for HIV-

positive individuals. The majority of the 119 CpG sites were located within or near

genes that are involved in known HIV pathology and progression. The results from DMR

analysis are corresponding to some of the significant genes for frailty. For example,

cg26312951, cg22862003 and cg21549285 from the 119 CpG sites are located in the

MX1 gene (Interferon-Induced GTP-Binding Protein Mx1) and were negatively

associated with frailty. A DMR on *MX1* also showed a significant with frailty. *MX1*

encodes a GTP-metabolizing protein induced by interferon I and II and is involved in

interferon gamma signaling and Toll-like signaling pathway. Multiple CpGs near the

HLA-F and *HLA-E* genes are part of the predictive panel, and these two genes are

actively involved in immune response (54). Our previously reported HIV-associated

CpG site, cg07839457 in the *NLRC5* gene is also a member of the predictive panel on

frailty (25). Other interesting gene regions reveled by DMR analysis include *PARP9 and*

IFI44L, which both genes are involved in *HIV pathogenesis.* The biological relevance of

these 119 CpG sites was further supported by the gene ontology enrichment analysis.

The top enriched pathways such as type I interferon response and cytokine response

may point out important biological pathways that leads to frailty and increased risk of

mortality among people living with HIV.

351   We acknowledge several limitations in this study. The generalizability of the

selected CpG sites may be limited since our samples were predominantly middle-aged

men, which may not generalize to frailty in a different age group. All samples in our

study are HIV-positive and the identified CpGs have a limited application to HIV-

negative population as we discussed above. Future studies in diverse populations is

warranted to validate the selected methylation features. Lastly, the prediction of low

frailty is moderate due to imbalanced sample distribution in our present study. We

expect that including more samples with low frailty will improve the predictive

performance.

Conclusions

We identified a panel of 119 predictive DNAm features in blood that are associated with

frailty and mortality among people living with HIV. These DNAm features may serve as

biomarkers to discriminate high and low frailty groups and may help to prioritize genes

to better understand the mechanisms of frailty in HIV-positive population. These DNAm

features have potential to serve as biomarkers to monitor HIV progression in future

clinical care.

Legends

Figure 1: Flowchart of analytical procedures on selection of CpG sites in peripheral

blood methylome, machine learning prediction models to predict frailty, DNA

methylation score to assess mortality, and gene ontology enrichment analysis

Figure 2: Manhattan and quantile-quantile plots on Veteran Aging Cohort Study (VACS)

index (λ=1.038) in the training set; blue line indicates False Discovery Rate (FDR)=0.05

Figure 3: Differentially methylation regions (DMRs) are associated with frailty,

measured by Veteran Aging Cohort Study (VACS) index. a: *MX1* regional plot showing

methylation beta value among subjects with VACS index > 50 and VACS index ≤ 50 in

the training set. b: *IFI11L* regional plot showing methylation beta value among subjects

with VACS index > 50 and VACS index ≤ 50 in the training set. c: *PARP9* regional plot

showing methylation beta value among subjects with VACS index > 50 and VACS index

≤ 50 in the training set

Figure 4: Receiver operating characteristic curve by XGBoost prediction model on HIV

frailty; a) Predicting high HIV frailty (VACS index >50 vs. ≤50), Area Under Curve

(AUC): 0.830 (95% CI: 0.786,0.874); b) Predicting low HIV frailty (VACS index >16 vs.

≤16), AUC: 0.735 (95% CI: 0.688,0.782)

Figure 5: Kaplan-Meier curves comparing high and low HIV frailty methylation score

groups. Methylation score is calculated by 119 selected probes. High methylation score

group has methylation score >=0, while low methylation score group <0.

Figure 6: Gene ontology enrichment analysis of 119 CpG probes (FDR<0.05) for

prediction

Figure S1: Distribution of Veteran Aging Cohort Study index (VACS index) between

training set and testing set

Table 1: Study sample characteristics

Table 2: A panel of 119 CpG sites in blood that predicts high and low frailty in a HIV-

positive veteran population

Table 3: Performance of machine learning model predicting high and low frailty in an

HIV-positive population

Table 4: Gene ontology term enrichment analysis of the selected 119 CpG sites that

predict frailty in an HIV-positive population

Table S1: Differentially methylated regions between high and low frailty in training set

Table 2: A panel of 119 CpG sites in blood that predicts high and low frailty in a HIV-infected veteran population

CpG	Chr	Position	Gene	Gene group	Relation to CpG Island	Effect size	SE	P value	FDR*
cg01309328	6	32811253	*PSMB8*	Body	N_Shore	-5.30	0.888	4.44E-09	9.32E-04
cg08099136	6	32811251	*PSMB8*	Body	N_Shore	-4.77	0.800	4.63E-09	9.32E-04
cg26312951	21	42797847	*MX1*	TSS200;5UTR	N_Shore	-2.46	0.417	6.40E-09	9.32E-04
cg08818207	6	32820355	*TAP1*	Body	N_Shore	-3.40	0.627	9.17E-08	1.00E-02
cg08122652	3	122281939	*PARP9*	5UTR;TSS1500	N_Shore	-1.79	0.341	2.18E-07	1.45E-02
cg07352001	10	44144445	*ZNF32*	TSS200;TSS1500	Island	-14.30	2.730	2.31E-07	1.45E-02
cg07325529	6	6613762	*LY86*	Body		20.70	3.980	2.77E-07	1.45E-02
cg16242615	19	4059988	*ZBTB7A*	5UTR	Island	-6.27	1.200	2.85E-07	1.45E-02
cg00533183	6	32810742	*PSMB8*	Body	N_Shore	-5.81	1.120	3.18E-07	1.45E-02
cg12649038	10	116282534	*ABLIM1*	5UTR		5.03	0.973	3.32E-07	1.45E-02
cg08926253	11	614761	*IRF7*	Body	Island	-2.91	0.571	4.94E-07	1.96E-02
cg03038262	11	315262	*IFITM1*	3UTR	N_Shore	-2.86	0.565	5.83E-07	2.12E-02
cg07839457	16	57023022	*NLRC5*	TSS1500	N_Shore	-1.99	0.396	6.55E-07	2.12E-02
cg22930808	3	122281881	*PARP9*	5UTR	N_Shore	-1.54	0.306	6.78E-07	2.12E-02
cg03607951	1	79085586	*IFI44L*	TSS1500		-2.00	0.398	7.41E-07	2.16E-02
cg08260450	6	34993987	*ANKS1A*	Body		6.35	1.270	8.43E-07	2.30E-02
cg03917473	17	38764244				9.10	1.840	1.04E-06	2.67E-02
cg18234224	1	172917851				6.59	1.350	1.34E-06	3.22E-02
cg06188083	10	91093005	*IFIT3*	Body		-2.02	0.414	1.40E-06	3.22E-02
cg23570810	11	315102	*IFITM1*	Body	N_Shore	-2.31	0.475	1.58E-06	3.41E-02
cg03816851	22	18324769	*MICAL3*	Body	Island	10.30	2.120	1.64E-06	3.41E-02
cg20676542	17	54991456	*TRIM25*	TSS200	Island	-3.02	0.629	2.10E-06	4.17E-02
cg05019807	9	139410393	*NOTCH1*	Body	N_Shore	5.97	1.260	2.70E-06	5.07E-02
cg03753191	13	43566902	*EPSTI1*	TSS1500	S_Shore	-5.39	1.140	2.88E-06	5.07E-02
cg01971407	11	313624	*IFITM1*	TSS1500	N_Shelf	-3.53	0.745	2.90E-06	5.07E-02
cg03359362	19	47289611	*SLC1A5*	TSS1500;Body;5UTR	N_Shore	-12.60	2.670	3.13E-06	5.10E-02
cg22116398	5	196162			S_Shore	5.15	1.090	3.15E-06	5.10E-02
cg26922780	16	88769443	*RNF166*	Body	N_Shelf	4.27	0.907	3.28E-06	5.12E-02
cg15748006	2	9772375	*YWHAQ*	TSS1500	S_Shore	4.45	0.949	3.45E-06	5.20E-02

cg22862003	21	42797588	MX1	TSS1500;5UTR	N_Shore	-1.66	0.356	3.88E-06	5.65E-02
cg21366673	6	30459512	HLA-E	Body	S_Shore	-4.19	0.900	4.04E-06	5.69E-02
cg05588757	2	95825608	ZNF514	TSS1500	Island	-19.40	4.220	5.25E-06	6.64E-02
cg06872964	1	79085250	IFI44L	TSS1500		-1.92	0.416	5.26E-06	6.64E-02
cg06376949	10	91173811	IFIT5	TSS1500	N_Shore	-3.21	0.698	5.29E-06	6.64E-02
cg01154505	2	112940409	FBLN7	Body	S_Shore	6.16	1.340	5.32E-06	6.64E-02
cg01871595	13	39336304	FREM2	Body		6.90	1.500	5.59E-06	6.78E-02
cg05696877	1	79088769	IFI44L	5UTR		-1.21	0.265	6.01E-06	6.94E-02
cg24497541	1	55352819	DHCR24	1stExon;5UTR	Island	-9.81	2.150	6.12E-06	6.94E-02
cg11829870	22	50988451	KLHDC7B	3UTR;1stExon	S_Shore	-3.63	0.795	6.28E-06	6.94E-02
cg13720750	5	112309167			N_Shelf	7.28	1.600	6.37E-06	6.94E-02
cg18255813	6	7195966	RREB1	Body		9.38	2.060	6.76E-06	6.94E-02
cg21549285	21	42799141	MX1	5UTR	S_Shore	-1.01	0.224	7.08E-06	6.94E-02
cg14945867	14	54908007	CNIH	1stExon	Island	-29.70	6.550	7.16E-06	6.94E-02
cg09026253	11	313267	IFITM1	TSS1500	S_Shore	-3.48	0.768	7.25E-06	6.94E-02
cg14651616	11	64563992	MAP4K2	Body		-6.98	1.540	7.27E-06	6.94E-02
cg24082730	3	126076366	KLF15	TSS200	Island	-10.90	2.410	7.31E-06	6.94E-02
cg16302816	11	16834800	PLEKHA7	Body		6.50	1.440	7.49E-06	6.96E-02
cg01765174	9	100880960	TRIM14	Body	N_Shore	-4.47	0.993	8.35E-06	7.60E-02
cg10552523	11	313478	IFITM1	TSS1500	N_Shelf	-3.14	0.702	9.42E-06	8.40E-02
cg19025187	3	195808255	TFRC	5UTR	N_Shore	-6.73	1.510	1.07E-05	9.16E-02
cg21081878	21	38334730	HLCS	5UTR	N_Shelf	3.49	0.785	1.08E-05	9.16E-02
cg14299044	10	19972179				5.32	1.200	1.09E-05	9.16E-02
cg24871132	3	149688846	PFN2	TSS200	Island	-21.70	4.900	1.17E-05	9.55E-02
cg27294701	16	88107336	BANP	Body	Island	7.04	1.590	1.18E-05	9.55E-02
cg09296453	6	29692035	HLA-F	Body	Island	-3.24	0.735	1.31E-05	1.04E-01
cg16400434	11	73882363	PPME1;C2CD3	TSS200;TSS1500	Island	-25.60	5.850	1.46E-05	1.13E-01
cg16656286	17	4981603	ZFP3	TSS200	Island	22.40	5.130	1.52E-05	1.13E-01
cg26480543	19	55629279	PPP1R12C	TSS1500	S_Shore	-7.33	1.680	1.52E-05	1.13E-01
cg19371652	12	113415883	OAS2	TSS1500		-3.59	0.822	1.52E-05	1.13E-01
cg09597638	17	3907349			N_Shore	-5.48	1.260	1.56E-05	1.14E-01
cg00994629	14	22694547				-7.44	1.710	1.62E-05	1.16E-01

cg02314339	10	910206653				-4.35	1.010	1.86E-05	1.29E-01
cg21468416	9	127019914	NEK6	1stExon;TSS1500;5UTR	N_Shore	6.61	1.530	1.89E-05	1.29E-01
cg12149905	3	61547208	PTPRG	TSS200	Island	-12.20	2.820	1.89E-05	1.29E-01
cg20927242	6	29692011	HLA-F	Body	Island	-7.14	1.660	1.97E-05	1.32E-01
cg03332034	16	1823786	EME2; MRPS34	TSS1500	Island	-12.30	2.870	2.12E-05	1.36E-01
cg05489271	12	123871695	SETD8	Body	N_Shelf	7.83	1.820	2.13E-05	1.36E-01
cg25843003	6	31431312	HCP5	3UTR		-3.29	0.768	2.19E-05	1.36E-01
cg14090510	7	64839023	ZNF92	5UTR;Body	Island	-14.70	3.440	2.21E-05	1.36E-01
cg25467833	1	212335061				4.86	1.140	2.28E-05	1.36E-01
cg03725115	6	30458102	HLA-E	Body	Island	-5.09	1.190	2.29E-05	1.36E-01
cg15620384	6	34164405			Island	-6.69	1.570	2.34E-05	1.36E-01
cg08450404	19	58326441	ZNF552	TSS200	S_Shore	-8.37	1.960	2.35E-05	1.36E-01
cg06927297	12	117175889	RNFT2	TSS200;TSS1500	Island	-27.60	6.460	2.36E-05	1.36E-01
cg21684411	6	31431573	HCP5	3UTR		-6.71	1.570	2.40E-05	1.36E-01
cg20998539	17	62208374	ERN1	TSS1500	S_Shore	-7.32	1.720	2.42E-05	1.36E-01
cg25138854	1	9555557			Island	-7.03	1.650	2.45E-05	1.36E-01
cg13250752	4	138281992				-6.09	1.430	2.46E-05	1.36E-01
cg26562691	16	23850404	PRKCB	Body	S_Shelf	6.87	1.620	2.47E-05	1.36E-01
cg23677352	4	149715675				-7.92	1.860	2.49E-05	1.36E-01
cg22107533	15	45028083	TRIM69	TSS1500		-3.14	0.739	2.53E-05	1.36E-01
cg06412917	12	124858844	NCOR2	Body	S_Shelf	6.47	1.520	2.57E-05	1.37E-01
cg01190666	20	62204908	PRIC285	5UTR	N_Shore	-3.47	0.818	2.67E-05	1.40E-01
cg11977562	13	114845297	RASA3	Body	N_Shelf	7.05	1.660	2.70E-05	1.40E-01
cg13304609	1	79085162	IFI44L	TSS1500		-1.54	0.364	2.72E-05	1.40E-01
cg01537765	19	42914828	LIPE	Body	Island	22.00	5.210	2.75E-05	1.40E-01
cg08275025	11	314493	IFITM1	Body	N_Shore	-4.98	1.180	2.78E-05	1.40E-01
cg05362517	13	37393368	RFXAP	5UTR;1stExon	Island	-13.80	3.260	2.92E-05	1.42E-01
cg21145248	5	176816679	SLC34A1	Body		6.04	1.430	2.94E-05	1.42E-01
cg07537655	6	161415612	MAP3K4	Body	S_Shelf	1.77	0.419	2.95E-05	1.42E-01
cg26912671	1	66458803	PDE4B	1stExon		10.70	2.540	3.01E-05	1.42E-01

cg11905821	6	31770932	*LSM2*	Body	N_Shelf	11.80	2.800	3.05E-05	1.42E-01
cg06202053	11	64109021	*CCDC88B*	Body	N_Shore	-5.84	1.390	3.09E-05	1.42E-01
cg13794687	7	123302399	*LMOD2*	Body		6.73	1.600	3.11E-05	1.42E-01
cg23892836	6	29692085	*HLA-F*	Body	Island	-3.19	0.759	3.12E-05	1.42E-01
cg15331332	6	29692111	*HLA-F*	Body	S_Shore	-3.53	0.840	3.12E-05	1.42E-01
cg15804432	15	64454965	*PPIB*	Body	Island	-4.27	1.020	3.15E-05	1.42E-01
cg09251764	17	6659070	*XAF1*	TSS200		-5.73	1.370	3.23E-05	1.44E-01
cg20893717	7	100318190	*EPO*	TSS1500	Island	13.80	3.290	3.26E-05	1.44E-01
cg08159663	16	57022486	*NLRC5*	TSS1500	N_Shore	-3.44	0.821	3.29E-05	1.44E-01
cg10019429	19	32836659	*ZNF507*	1stExon;5UTR	Island	-17.20	4.120	3.55E-05	1.54E-01
cg11791770	11	611791	*PHRF1*	3UTR	Island	-6.52	1.560	3.64E-05	1.56E-01
cg11653134	2	66805547			S_Shore	-4.24	1.020	3.81E-05	1.61E-01
cg06981309	3	146260954	*PLSCR1*	5UTR	N_Shore	-1.96	0.471	3.84E-05	1.61E-01
cg07168939	8	143763412	*PSCA*	Body		-5.88	1.420	3.88E-05	1.61E-01
cg04611649	2	152681240	*ARL5A*	5UTR	N_Shelf	7.42	1.790	4.04E-05	1.66E-01
cg16297569	1	92952517	*GFI1*	TSS1500;TSS200	Island	-8.34	2.020	4.16E-05	1.70E-01
cg01518846	6	26246970	*HIST1H4G*	1stExon	Island	-17.50	4.240	4.41E-05	1.74E-01
cg26852894	4	11157341				6.31	1.530	4.42E-05	1.74E-01
cg06811183	3	48510438	*SHISA5*	3UTR		-8.23	2.000	4.42E-05	1.74E-01
ch.10.1305203R	10	63407435				-8.63	2.090	4.43E-05	1.74E-01
cg12461141	11	5710654	*TRIM22*	TSS1500		-3.40	0.829	4.79E-05	1.87E-01
cg13149600	21	43374220	*C2CD2*	TSS1500	S_Shore	-9.35	2.280	4.83E-05	1.87E-01
cg12660813	1	3192343	*PRDM16*	Body	N_Shelf	7.28	1.780	4.96E-05	1.89E-01
cg24447788	19	795310			N_Shore	11.30	2.760	5.02E-05	1.89E-01
cg13861758	9	138148099			N_Shelf	5.08	1.240	5.02E-05	1.89E-01
cg09950208	10	130841235				-4.99	1.220	5.24E-05	1.95E-01
cg01482620	19	48835971	*TMEM143*	3UTR	N_Shore	18.40	4.500	5.28E-05	1.95E-01
cg03634735	7	1992524	*MAD1L1*	Body	S_Shore	6.19	1.520	5.37E-05	1.97E-01

*FDR: False discovery rate

Table S1: Differentially methylated regions between high and low fraity in training set

chr	start	end	value	area	Number of CpG	p.value	fwer	Gene.Symbol	FDR	CpG
3	122281881	122281975	-0.068	0.203	3	2.30E-07	0.001	*DTX3L,PARP9*	1.03E-04	cg00959259; cg08122652; cg22930808
12	11700321	11700489	-0.054	0.162	3	1.61E-06	0.006	*LINC01252*	3.60E-04	cg06202470; cg18232235; cg19651115
1	79088769	79118191	-0.039	0.154	4	1.17E-05	0.049	*IFI44,IFI44L*	1.75E-03	cg00458211; cg01079652; cg05696877; cg07107453
21	42797588	42797847	-0.046	0.092	2	2.41E-05	0.081	*MX1*	2.68E-03	cg22862003; cg26312951
1	79085162	79085765	-0.034	0.168	5	2.99E-05	0.122	*IFI44L*	2.68E-03	cg00855901; cg03607951; cg06872964; cg13304609; cg17980508
11	319555	319718	-0.036	0.109	3	4.73E-05	0.166	*IFITM3*	2.80E-03	cg20045320; cg09122035; cg17990365
11	312518	313624	-0.023	0.230	10	4.89E-05	0.194	*IFITM1*	2.80E-03	cg01886988; cg01971407; cg04582010; cg05432003; cg09026253; cg10552523; cg11694510; cg20566897; cg22963452; cg27032101
11	314493	317767	-0.021	0.228	11	5.01E-05	0.195	*IFITM1*	2.80E-03	cg12047941; cg15013527; cg25050332; cg27331665; cg03038262; cg08000731; cg08275025; cg16379091; cg18434560; cg21686213; cg23570810
21	42798747	42799141	-0.041	0.083	2	5.95E-05	0.197	*MX1*	2.96E-03	cg08924203; cg21549285

List of abbreviations

AUC: Area Under Curve

CI: Confidence interval

DMR: differentially methylated region

DNA: Deoxyribonucleic acid

DNAm: DNA methylation

DAVID: Database for Annotation, Visualization and Integrated Discovery

EWAS: epigenome-wide association study

FDR: False discovery rate

FWER: Family-wise error rate

GLMNET: Lasso and Elastic-Net Regularized Generalized Linear Models

GO: Gene ontology

HIV: Human immunodeficiency virus

HM450K: Human Methylation 450K BeadChip

NK: Natural killer

PC: Principal component

QC: Quality control

SVM: Support Vector Machines

VACS: Veterans Aging Cohort Study

VACS index: Veterans Aging Cohort Study index

XGBoost: Extreme Gradient Boosting Tree

Declarations

Ethics approval and consent to participate

The study was approved by the committee of the Human Research Subject Protection

at Yale University and the Institutional Research Board Committee of the Connecticut

Veteran Healthcare System. All subjects provided written consents.

Availability of data and materials

Demographic and clinical variables and DNAm data for the VACS samples were

submitted to GEO dataset (GSE117861) and are available to the public. All codes for

analysis are also available upon a request to the corresponding author.

Competing interests

The authors declare that they have no competing interests.

Funding

The project was supported by the National Institute on Drug Abuse (R03DA039745,

R01DA038632, R01DA047063, R01DA047820) and the National Center for Post-

Traumatic Stress Disorder, USA.

Authors' contributions

CS was responsible for data analysis and manuscript preparation. ACJ provided DNA

samples, clinical data, and contributed to manuscript preparation. XZ was responsible

for the bioinformatics data processing. VM involved clinical data collection and

manuscript preparation. DH and EJ contributed to analytical approach and the

manuscript preparation. KX was responsible for the study design, study protocol,

sample preparation, data analysis, interpretation of findings, and manuscript

preparation.

452 ***Acknowledgements***

453 The authors appreciate the support of the Veteran Aging Study Cohort Biomarker Core

454 and Yale Center of Genomic Analysis.

References

1.   Kooij KW, Wit FW, Schouten J, van der Valk M, Godfried MH, Stolte IG, et al. HIV infection is independently associated with frailty in middle-aged HIV type 1-infected individuals compared with similar but uninfected controls. AIDS. 2016;30(2):241-50.

2.   Dent E, Kowal P, Hoogendijk EO. Frailty measurement in research and clinical practice: A review. Eur J Intern Med. 2016;31:3-10.

3.   Lam K, Pan K, Linnekamp JF, Medema JP, Kandimalla R. DNA methylation based biomarkers in colorectal cancer: a systematic review. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer. 2016;1866(1):106-20.

4.   Teroganova N, Girshkin L, Suter CM, Green MJ. DNA methylation in peripheral tissue of schizophrenia and bipolar disorder: a systematic review. BMC genetics. 2016;17(1):27.

5.   Bakusic J, Schaufeli W, Claes S, Godderis L. Stress, burnout and depression: A systematic review on DNA methylation mechanisms. Journal of Psychosomatic Research. 2017;92:34-44.

6.   Li M, D'Arcy C, Li X, Zhang T, Joober R, Meng X. What do DNA methylation studies tell us about depression? A systematic review. Translational psychiatry. 2019;9(1):68.

7.   Horvath S. DNA methylation age of human tissues and cell types. Genome biology. 2013;14(10):3156.

8.   Horvath S, Raj K. DNA methylation-based biomarkers and the epigenetic clock theory of ageing. Nature Reviews Genetics. 2018:1.

9.   Hannum G, Guinney J, Zhao L, Zhang L, Hughes G, Sadda S, et al. Genome-wide methylation profiles reveal quantitative views of human aging rates. Molecular cell. 2013;49(2):359-67.

10.   Liu C, Marioni RE, Hedman ÅK, Pfeiffer L, Tsai P-C, Reynolds LM, et al. A DNA methylation biomarker of alcohol consumption. Molecular psychiatry. 2018;23(2):422.

11.   Breitling LP, Yang R, Korn B, Burwinkel B, Brenner H. Tobacco-smoking-related differential DNA methylation: 27K discovery and replication. The American Journal of Human Genetics. 2011;88(4):450-7.

12.   Gao X, Zhang Y, Breitling LP, Brenner H. Relationship of tobacco smoking and smoking-related DNA methylation with epigenetic age acceleration. Oncotarget. 2016;7(30):46878-89.

13.   Joubert BR, Håberg SE, Nilsen RM, Wang X, Vollset SE, Murphy SK, et al. 450K epigenome-wide scan identifies differential DNA methylation in newborns related to maternal smoking during pregnancy. Environmental health perspectives. 2012;120(10):1425-31.

14.   Lee KW, Pausova Z. Cigarette smoking and DNA methylation. Frontiers in genetics. 2013;4:132.

15.   Zhang X, Hu Y, Aouizerat BE, Peng G, Marconi VC, Corley MJ, et al. Machine learning selected smoking-associated DNA methylation signatures that predict HIV prognosis and mortality. 2018;10(1):155.

16.   Zhang R, Miao Q, Wang C, Zhao R, Li W, Haile CN, et al. Genome-wide DNA methylation analysis in alcohol dependence. Addiction biology. 2013;18(2):392-403.

17.   Kraiczy J, Nayak KM, Howell KJ, Ross A, Forbester J, Salvestrini C, et al. DNA methylation defines regional identity of human intestinal epithelial organoids and undergoes dynamic changes during development. Gut. 2019;68(1):49-61.

18.   Nano J, Ghanbari M, Wang W, de Vries PS, Dhana K, Muka T, et al. Epigenome-Wide
Association Study Identifies Methylation Sites Associated With Liver Enzymes and Hepatic
Steatosis. Gastroenterology. 2017;153(4):1096-106.e2.
19.   Delpu Y, Cordelier P, Cho W, Torrisani J. DNA methylation and cancer diagnosis.
International journal of molecular sciences. 2013;14(7):15029-58.
20.   Figueroa ME, Lugthart S, Li Y, Erpelinck-Verschueren C, Deng X, Christos PJ, et al. DNA
methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer
cell. 2010;17(1):13-27.
21.   Holm K, Hegardt C, Staaf J, Vallon-Christersson J, Jönsson G, Olsson H, et al. Molecular
subtypes of breast cancer are associated with characteristic DNA methylation patterns. Breast
cancer research. 2010;12(3):R36.
22.   Berdasco M, Esteller M. Clinical epigenetics: seizing opportunities for translation. Nature
Reviews Genetics. 2019;20(2):109-27.
23.   Mohammad HP, Barbash O, Creasy CL. Targeting epigenetic modifications in cancer
therapy: erasing the roadmap to cancer. Nat Med. 2019;25(3):403-18.
24.   Erlandson KM, Ng DK, Jacobson LP, Margolick JB, Dobs AS, Palella Jr FJ, et al.
Inflammation, immune activation, immunosenescence, and hormonal biomarkers in the frailty-
related phenotype of men with or at risk for HIV infection. The Journal of infectious diseases.
2016;215(2):228-37.
25.   Zhang X, Justice AC, Hu Y, Wang Z, Zhao H, Wang G, et al. Epigenome-wide differential
DNA methylation between HIV-infected and uninfected individuals. Epigenetics.
2016;11(10):750-60.
26.   Chen J, Huang Y, Hui Q, Mathur R, Gwinn M, So-Armah K, et al. Epigenetic Associations
with Estimated Glomerular Filtration Rate (eGFR) among Men with HIV Infection. Clin Infect Dis.
2019.
27.   Mathur R, Hui Q, Huang Y, Gwinn M, So-Armah K, Freiberg MS, et al. DNA Methylation
Markers of Type 2 Diabetes Mellitus Among Male Veterans With or Without Human
Immunodeficiency Virus Infection. J Infect Dis. 2019;219(12):1959-62.
28.   Breitling LP, Saum K-U, Perna L, Schöttker B, Holleczek B, Brenner H. Frailty is associated
with the epigenetic clock but not with telomere length in a German cohort. Clinical Epigenetics.
2016;8(1):21.
29.   Sanchez-Conde M, Rodriguez-Centeno J, Dronda F, Lopez JC, Jimenez Z, Berenguer J, et
al. Frailty phenotype: a clinical marker of age acceleration in the older HIV-infected population.
Epigenomics. 2019;11(5):501-9.
30.   Horvath S, Levine AJ. HIV-1 infection accelerates age according to the epigenetic clock.
The Journal of infectious diseases. 2015;212(10):1563-73.
31.   Rickabaugh TM, Baxter RM, Sehl M, Sinsheimer JS, Hultin PM, Hultin LE, et al.
Acceleration of age-associated methylation patterns in HIV-1-infected adults. PloS one.
2015;10(3):e0119201.
32.   Gross AM, Jaeger PA, Kreisberg JF, Licon K, Jepsen KL, Khosroheidari M, et al.
Methylome-wide analysis of chronic HIV infection reveals five-year increase in biological age
and epigenetic targeting of HLA. Molecular cell. 2016;62(2):157-68.

33. Nelson KN, Hui Q, Rimland D, Xu K, Freiberg MS, Justice AC, et al. Identification of HIV
infection-related DNA methylation sites and advanced epigenetic aging in HIV-positive,
treatment-naive U.S. veterans. AIDS. 2017;31(4):571-5.
34. Marioni RE, Shah S, McRae AF, Chen BH, Colicino E, Harris SE, et al. DNA methylation age
of blood predicts all-cause mortality in later life. Genome biology. 2015;16(1):25.
35. Marioni RE, Harris SE, Shah S, McRae AF, von Zglinicki T, Martin-Ruiz C, et al. The
epigenetic clock and telomere length are independently associated with chronological age and
mortality. International journal of epidemiology. 2016;45(2):424-32.
36. Perna L, Zhang Y, Mons U, Holleczek B, Saum K-U, Brenner H. Epigenetic age
acceleration predicts cancer, cardiovascular, and all-cause mortality in a German case cohort.
Clinical epigenetics. 2016;8(1):64.
37. Christiansen L, Lenart A, Tan Q, Vaupel JW, Aviv A, McGue M, et al. DNA methylation
age is associated with mortality in a longitudinal Danish twin study. Aging Cell. 2016;15(1):149-
54.
38. Fransquet PD, Wrigglesworth J, Woods RL, Ernst ME, Ryan J. The epigenetic clock as a
predictor of disease and mortality risk: a systematic review and meta-analysis. Clin Epigenetics.
2019;11(1):62.
39. Zhang Y, Wilson R, Heiss J, Breitling LP, Saum K-U, Schöttker B, et al. DNA methylation
signatures in peripheral blood strongly predict all-cause mortality. Nature communications.
2017;8:14617.
40. Tate JP, Justice AC, Hughes MD, Bonnet F, Reiss P, Mocroft A, et al. An internationally
generalizable risk index for mortality after one year of antiretroviral therapy. Aids.
2013;27(4):563-72.
41. Justice AC, Dombrowski E, Conigliaro J, Fultz SL, Gibson D, Madenwald T, et al. Veterans
aging cohort study (VACS): overview and description. 2006;44(8 Suppl 2):S13.
42. Lehne B, Drong AW, Loh M, Zhang W, Scott WR, Tan S-T, et al. A coherent approach for
analysis of the Illumina HumanMethylation450 BeadChip improves data quality and
performance in epigenome-wide association studies. 2015;16(1):37.
43. Aryee MJ, Jaffe AE, Corrada-Bravo H, Ladd-Acosta C, Feinberg AP, Hansen KD, et al.
Minfi: a flexible and comprehensive Bioconductor package for the analysis of Infinium DNA
methylation microarrays. 2014;30(10):1363-9.
44. Jaffe AE, Murakami P, Lee H, Leek JT, Fallin MD, Feinberg AP, et al. Bump hunting to
identify differentially methylated regions in epigenetic epidemiology studies. Int J Epidemiol.
2012;41(1):200-9.
45. Bebu I, Tate J, Rimland D, Mesner O, Macalino GE, Ganesan A, et al. The VACS index
predicts mortality in a young, healthy HIV population starting highly active antiretroviral
therapy. Journal of acquired immune deficiency syndromes (1999). 2014;65(2):226.
46. Kuhn MJJoss. Building predictive models in R using the caret package. 2008;28(5):1-26.
47. Hastie T, Tibshirani R, Friedman J, Franklin J. The elements of statistical learning: data
mining, inference and prediction. The Mathematical Intelligencer. 2005;27(2):83-5.
48. Kotsiantis SB, Zaharakis I, Pintelas P. Supervised machine learning: A review of
classification techniques. Emerging artificial intelligence applications in computer engineering.
2007;160:3-24.

49.   Chen T, Guestrin C, editors. Xgboost: A scalable tree boosting system. Proceedings of the
22nd acm sigkdd international conference on knowledge discovery and data mining; 2016:
ACM.
50.   Ogutu JO, Piepho H-P, Schulz-Streeck T. A comparison of random forests, boosting and
support vector machines for genomic selection. BMC Proc. 2011;5 Suppl 3(Suppl 3):S11-S.
51.   Brodersen KH, Ong CS, Stephan KE, Buhmann JM, editors. The balanced accuracy and its
posterior distribution. 2010 20th International Conference on Pattern Recognition; 2010: IEEE.
52.   Fresno C, Fernández EAJB. RDAVIDWebService: a versatile R interface to DAVID.
2013;29(21):2810-1.
53.   Justice AC, Modur SP, Tate JP, Althoff KN, Jacobson LP, Gebo KA, et al. Predictive
accuracy of the Veterans Aging Cohort Study index for mortality with HIV infection: a North
American cross cohort analysis. Journal of acquired immune deficiency syndromes (1999).
2013;62(2):149-63.
54.   O'Callaghan CA, Bell JIJIr. Structure and function of the human MHC class Ib molecules
HLA-E, HLA-F and HLA-G. 1998;163(1):129-38.

Figure 1

Figure 2

Figure 3a

Figure 3b

Figure 3c

Figure 4

Figure 5

Figure 6